Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Rosetta Genomics to Restructure, Cut 20 Percent of Workforce

Rosetta Genomics to Restructure, Cut 20 Percent of Workforce

Oct 05, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today announced that it will undertake a restructuring that is expected to reduce the company's monthly burn rate 32 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Call to Expand

The editorial board of the Pittsburgh Post-Gazette says other lawmakers should take Florida's approach and provide additional protections against genetic discrimination.

Additional Suit

The Hill reports 17 states and the District of Columbia are suing over a new policy that would strip international students of their visas if they only attend classes online.

Racism in Public Health

Centers for Disease Control and Prevention employees call on the agency to label racism a public health crisis and examine its own policies, NPR reports.

PNAS Studies Look at Inca Resettlement, Spermatogonial Stem Cell Transcriptomes, More

In PNAS this week: genetic evidence for Inca resettlement, analysis of spermatogonial stem cell transcriptomes, and more.

Jul
22
Featured Webinar

Advances in Genetic Testing for IVF Research: PGT-A, PGT-M, and Carrier Screening

Sponsored by
Thermo Fisher Scientific

Luis A. Alcaraz, cofounder of Bioarray and Journey Genomics, accredited diagnostic and research labs based in Alicante, Spain, will review how his teams use advanced genomic techniques for carrier screening research as well as for preimplantation genetic testing (PGT) in embryos for both aneuploidies (PGT-A) and monogenic disorders (PGT-M).

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
19
Featured Webinar

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.